United Therapeutics discloses share count for $477.6 million ASR deal with Citi
A new 8-K specifies United Therapeutics will get an initial delivery of about 719,376 shares under its accelerated buyback with Citibank.
SEC filing
Latest
7 stories
Wednesday, September 23
Tuesday, September 8
Wednesday, August 12
Liquidia reports YUTREPIA sales growth, begins enrollment in L606 pivotal study
Second-quarter 2026 results show continued YUTREPIA uptake and the start of the Re-Spire pivotal study for L606, alongside a fourth straight profitable quarter.
SEC filing
Wednesday, August 5
United Therapeutics files two rare pulmonary disease NDAs, sets sights on approvals in 2027
The company said it submitted new drug applications for ralinepag tablets in PAH and Nebulized Tyvaso in IPF, with more filings and organ program milestones expected by year end.
SEC filing
MannKind reports Q2 2026 results with pediatric Afrezza and Furoscix ReadyFlow approvals
MannKind said it hit three 2026 catalysts in the quarter, including FDA approvals for pediatric Afrezza and the Furoscix ReadyFlow autoinjector, plus positive nintedanib DPI Phase 1b data.
SEC filing
Tuesday, August 4
FDA approves manufacturing supplement for Orenitram tablets from UNITED THERAP
Thursday, July 23
United Therapeutics names Victor Dzau to board of directors
The public benefit corporation appointed the former National Academy of Medicine president to its board effective July 22, 2026, expanding the board to 13 members.
SEC filing